Figure 3.
Comparison of biological and biochemical properties among five licensed liquid intravenous immunoglobulin preparations
| Components | Anti-Aa | Anti-Ba | IgA (ng/mg IgG) | Polymers (%) | Dimers (%) | Monomers (%) | Fragments (%) | C1q (AU) | C5a (%)b |
|---|---|---|---|---|---|---|---|---|---|
| ClairYg® | 0·11 ± 0·03 | 0·11 ± 0·01 | 301 ± 148 | 1·3 ± 0·2 | 7·0 ± 0·3 | 91·2 ± 0·1 | 0·5 ± 0·1 | 0·42 ± 0·04 | 14 ± 1·5 |
| Octagam® | 0·11 ± 0·01 | 0·08 ± 0·03 | 820 ± 170 | 1·0 ± 0·1 | 6·8 ± 1·4 | 91·6 ± 1·4 | 0·6 ± 0·1 | 1·66 ± 0·14 | 32 ± 1·7 |
| Kiovig® | 0·33 ± 0·03 | 0·42 ± 0·05 | 500 ± 46 | 1·2 ± 0·2 | 11·2 ± 1·3 | 86·8 ± 1·5 | 0·7 ± 0·1 | 0·67 ± 0·22 | 26 ± 1·0 |
| Privigen® | 0·64 ± 0·01 | 0·46 ± 0·02 | 165 ± 46 | 0·7 ± 0·1 | 8·8 ± 0·7 | 89·5 ± 0·8 | 1·1 ± 0·2 | 0·55 ± 0·11 | 21 ± 1·0 |
| Gamunex® | 0·69 ± 0·04 | 0·46 ± 0·03 | 385 ± 17 | 0·9 ± 0·1 | 5·1 ± 0·2 | 93·0 ± 0·2 | 1·0 ± 0·1 | 1·89 ± 0·37 | 35 ± 2·1 |
AU, arbitrary unit.
Data are mean ± SD (n = 3).
a
Ratio between tested sample and EDQM positive control Y0001152.
b
Percentage of activation vs. maximum complement activation using LPS.